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Abstract: Amphotericin B lipid complex (ABLC) was introduced in the late 1990s as a 
less toxic alternative to amphotericin B (AmB) deoxycholate. ABLC is a safe and effective 
broad-spectrum drug in the treatment of invasive fungal infections in patients with infection 
refractory to AmB deoxycholate or in patients intolerant of the same formulation. The drug has 
not been rigorously evaluated for primary therapy. Recent availability of several newer potent 
and safe drugs has sharply curtailed the use of potentially nephrotoxic ABLC. However, AmB 
lipid complex is likely to continue to play a limited albeit signiﬁ  cant clinical role in view of 
the narrow spectrum of activity and signiﬁ  cant drug-drug interactions of the newer drugs and 
emergence of drug-resistant fungi.
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Introduction
Incidence of invasive fungal infections is steadily on the rise over the past few decades, 
mainly due to an increase in the number of immunocompromised hosts, increasing 
number of older patients, and a sharp increase in the use of vascular and other devices 
(Ostrosky-Zeichner and Pappas 2006; Chamilos et al 2006; Martin et al 2003). Such 
infections, in the setting of compromised host defenses, are associated with considerable 
morbidity and mortality. Until 2 decades ago, amphotercin B (AmB) deoxycholate 
(a polyene) and narrow-spectrum ﬂ  ucytosine were the only available systemic anti-
fungal drugs; serious nephrotoxicity associated with AmB has long hampered its 
liberal use. Arrival of a safer class of drugs, triazoles, particularly ﬂ  uconazole, made 
an enormous impact in the outcome of patients with systemic candidiasis. In the late 
1990s, almost 40 years after the introduction of AmB deoxycholate, three lipid-based 
AmB formulations, namely AmB lipid complex (ABLC), AmB colloidal dispersion 
(ABCD) and liposomal AmB were developed to reduce nephrotoxicity without com-
promising efﬁ  cacy. Additionally, within the past decade, newer triazoles (voriconazole, 
posaconazole) and echinocandins (caspofungin, micafungin, and anidulafungin) have 
become available, thus now providing several choices to the clinician.
Availability of a large number of antifungal drugs within a relatively short period 
has led to clinical dilemmas regarding the appropriate uses of ‘newer’, as well as 
‘older’ drugs. This review focuses on the data on the efﬁ  cacy and safety of AmB 
lipid complex and highlights the role of polyenes in the current clinical scene of 
changing fungal epidemiology, emergence of antifungal resistance, and expanding 
at-risk populations.
AmB remains the antifungal drug with the broadest spectrum of activity, effec-
tive against almost all clinically relevant yeasts and molds. Exceptions to the rule Therapeutics and Clinical Risk Management 2008:4(6) 1286
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include Candida lusitaniae (about 20% resistance), Candida 
guilliermondi (Hawkins and Baddour 2003), Aspergillus 
terreus (Sutton et al 1999), and Scedosporium species 
(Gilgado et al 2006). All 3 lipid forms of AmB exhibit similar 
spectrum of activity in vitro.
ABLC consists of AmB complexed with 2 phospholipids 
in a 1:1 drug to lipid molar ratio. The 2 phospholip-
ids L-α-dimyristoylphosphatidyl choline (DMPC) and 
L-α-dimyristoyl phosphatidylglycerol (DMPG) are present in 
a 7:3 molar ratio (Janoff et al 1993). ABLC is characterized 
by lipid stabilized AmB aggregates appearing as ribbon-like 
structures. After iv administration, ABLC is rapidly cleared 
from the blood, and high concentrations are sequestered in 
the reticuloendothelial tissues in the liver, spleen, and lung 
(Adedoyin et al 1997). At the infected tissue sites, AmB is 
thought to be selectively released from the lipid complex by 
the fungal lipases. The 3 lipid forms of AmB have distinct 
pharmacological proﬁ  les. For example, in the immunocom-
promised mouse model of invasive pulmonary-aspergillosis, 
ABLC (5 mg/kg/d) produced a more rapid fungal clearance 
than liposomal AmB (5 mg/kg/d) suggesting that ABLC may 
deliver active amphotericin to the lung more rapidly than 
liposomal AmB (Lewis et al 2007).
ABLC is US FDA approved for use as second-line 
therapy for the treatment of systemic fungal infections in 
patients who are refractory to or intolerant of conventional 
AmB or other systemic antifunal agents, have renal impair-
ment or other contraindications to AmB, or have developed 
AmB nephrotoxicity. Most of the studies with ABLC were 
conducted during the 1990s, and hence comparative data 
with the newer triazoles and echinocandins are not available. 
Such comparative studies are unlikely to be performed. The 
dose recommended for use is 5 mg/kg/d, given as a single 
iv infusion, for all patients including those with liver or 
renal disease.
Data leading to the US FDA approval for clinical use 
of ABLC were derived from 556 cases of invasive fungal 
infections collected through an open-label, single-patient, 
emergency-use study of patients who were refractory to or 
intolerant of antifungal therapy (Walsh et al 1998). Most 
of these patients had received prior AmB deoxycholate. 
A second major data source is the industry supported CLEAR 
(Collaborative Exchange of Antifungal Research) registry 
which provides data on the efﬁ  cacy and renal safety of ABLC 
from data on 3514 patients who had received the drug during 
1996 to 2000 at 160 North American institutions (Pappas 
2005) (Table 1). These registry data have many limitations: 
the registry is retrospective; data collection was based on 
voluntary reporting with possible selection bias; objectively 
deﬁ  ned response criteria were lacking; and follow-up of 
patients was limited. The present review is largely based on 
the data from the above 2 sources, combined with available 
recent data (2003–2007).
Table 1 Demographic characteristics of all patients registered 
in the Collaborative Exchange of Antifungal Research (CLEAR) 
database (N = 3514)
Characteristic Value
Age, median (range), years 46 (1–97)
Sex
 Male 2039  (58)
 Female 1466  (42)
 Unknown 9 (1)
Reason for starting therapy with ABLC
  Refractory to prior antifungals 1411 (40)
  Underlying renal disease and prior antifungal 84 (2)
  Underlying renal disease and no prior antifungal 945 (27)
  Intolerant of prior antifungals 573 (16)
  No prior antifungal/no renal disease 431 (12)
 First-line  therapy  with  ABLCa 1376 (39)
 Unknown 57  (2)
 Other 13 (1)
Underlying medical conditions and procedures
 Hematologic  disorders
   Leukemia 1342  (38)
   Lymphoma 285  (8)
    Myelodysplastic syndrome 76 (2)
   Aplastic anemia 53 (2)
   Fanconi  anemia 11 (1)
 Stem-cell  transplantation
   Allogeneic BMT 728 (21)
   Autologous BMT 135 (4)
   PSCT 171  (5)
    Solid-organ transplantation 723 (21)
    Solid tumor 344 (10)
   Diabetes 261  (7)
   AIDS 156  (4)
    Renal disease 1111 (32)
    Steroid therapy 524 (14.9)
   Other 937  (27)
Note: Data are no. (%) of patients, except where noted. Patients may have had 1 
primary underlying condition.
aFirst-line therapy was deﬁ  ned as categories of no prior antifungal/no renal disease 
or underlying renal disease with no prior antifungal.
Abbreviations: ABLC, amphotericin B lipid complex; BMT, bone-marrow 
transplantation; GVHD, graft-versus-host disease; PSCT, peripheral stem-cell trans-
plantation.
Adapted with permission from Pappas PG (ed). 2005.  Amphotericin B lipid complex in the 
treatment of invasive fungal infections: results of the Collaborative Exchange of  Antifungal 
Research (CLEAR), an industry-supported patient registry. Clin Infect Dis, 40(Suppl 6):
S379–S83. Copyright © 2005. University of Chicago Press. All rights reserved.Therapeutics and Clinical Risk Management 2008:4(6) 1287
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Invasive candidiasis/candidemia
In the emergency-use study, the overall response rate for 
patients with candidiasis (n = 91) was 71% (Walsh et al 
1998). Responses were: 67% in disseminated candidiasis 
(n = 42); 75% in fungemia (n = 20); and 76% in single-organ 
candidiasis (n = 20). No difference in therapeutic responses 
was noted for the different candida species. In the large col-
laborative exchange of antifungal research (CLEAR) cohort 
registry, ABLC achieved 61% response ( cured or/ improved) 
rate in 920 patients infected (invasive or noninvasive) with 
candida species; clinical responses were similar in patients 
infected with C. albicans and non-albicans candida species 
(Ito and Hooshmand-Rad 2005) . Greater than 60% response 
rate was documented in patients infected with either Candida 
krusei or Candida glabrata (Table 2). Response rates to 
C. lusitaniae and C. guilliermondii were 56% (5 of 9 cases) 
and 33% (2 of 6 csaes), respectively. In a small (n = 74) 
Spanish cohort of patients with hematologic malignancies, 
complete/partial response was noted in 6 of 11 patients with 
invasive candidiasis; ABLC, administered at 3 mg/kg/d, was 
well tolerated (Martino et al 2005).
For invasive candidiasis, the role of polyenes has 
markedly diminished with the availability of better-tolerated 
echinocandins and the newer azoles. Echinocandins 
have good efficacy against fluconazole-susceptible and 
ﬂ  uconazole-resistant candidal species; the newer azoles, 
voriconazole and posaconazole, have good activity 
against fluconazole-susceptible candidal species and 
ﬂ  uconazole-resistant C.krusei, but their activity against 
ﬂ  uconazole-resistant C. glabrata is suboptimal.
Invasive aspergillosis (IA)
A prospective, randomized trial (of 277 patients) published 
in 2002 demonstrated voriconazole to be superior in efﬁ  cacy 
and survival to AmB deoxycholate (1–1.5 mg/kg/d) in the 
therapy of invasive aspergillosis (Herbrecht et al 2002). 
Response rates of voriconazole and AmB in the overall 
study population were 52.8% and 31.6%, respectively. Of 
interest, in the allogeneic stem cell group, the response rates 
were much lower for both drugs (32.7% for voriconazole and 
13.2% for AmB). Since this landmark study, voriconazole 
has been accepted as the initial choice of therapy; however, 
it is noteworthy that the trial did not use a lipid form of AmB 
as a comparator and most patients in the AmB deoxycholate 
arm had to stop therapy due to drug intolerance. Availability 
of oral and intravenous formulations and good tolerability 
proﬁ  le make voriconazole an attractive agent; however, 
the drug may not be an optimal choice in all situations. For 
example, patients with breakthrough infection while on 
mold-active azole prophylaxis, patients with serious hepatic 
impairment, patients with serious cardiac risk factors (eg, QT 
interval prolongation) and patients with possible concomitant 
Table 2 Clinical response to treatment with ABLC in patients with candidiasis, by prior treatment status
Refractory Underlying renal disease
Type 
of infection
To all prior 
antifungal 
therapy
To prior
azole
With prior 
antifungal 
therapy
With 
no prior 
antifungal 
therapy
Intolerant 
of prior 
antifungal 
therapy
No prior 
antifungal 
therapy/ no 
underlying 
renal disease
First-line 
therapy 
with ABLCa
Second-line 
therapy 
with ABLCb
C. albicans 
(n = 364)
93/139 (67) 67/104 (64) 7/12 (58) 65/115 (57) 28/50(56) 29/43(67) 94/158(60) 128/201(64)
Non-albicans 
Candida species 
(n = 375)
105/174 (60) 77/125 (62) 11/14 (79) 57/96 (59) 27/52 (52) 28/34 (82) 85/130 (65) 143/240 (60)
C. albicans + 
non-albicans 
Candida species 
(n = 90)
29/44 (66) 23/53 (66) 2/2 (100) 12/19 (63) 6/9 (67) 9/16 (56) 21/35 (60) 37/55 (67)
Multiple 
non-albicans 
Candida species 
(n = 25)
8/15 (53) 6/11 (55) ½ (50) 0/2 (0) 1/3 (33) 0/2 (0) 0/4 (0) 0/20 (50)
Total 235/372 (63) 173/293 (59) 21/30 (70) 134/232 (58) 62/114 (54) 66/95 (70) 200/327 (61) 318/516 (62)
Reproduced with permission from Ito JI, Hooshmand-Rad R. 2005.   Treatment of Candida infections with amphotericin B lipid complex. Clin Infect Dis, 40(Suppl 6):S384–91. 
Copyright © 2005. University of Chicago Press. All rights reserved.
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zygomycosis are not good candidates for voriconazole. Also, 
in voriconazole-intolerant or voriconazole-failed cases of IA, 
a polyene or an echinocandin must be considered.
The CLEAR registry assessed 398 patients with IA 
receiving ABLC (median dose 4.8 mg/kg/d) (Chandrasekar 
and Ito 2005). Common underlying conditions were: 
hematopoietic stem cell transplantaion (25%), hematologic 
malignancy 25%; and solid organ transplantation 27%. Failure 
of prior antifungal therapy (mostly AmB deoxycholate) was 
the primary reason for study enrollment. Cure or improved 
response was seen in 44% patients and a stable response 
in additional 21% patients (Table 3). No antagonism was 
observed when ABLC was administered after itraconazole 
exposure. When therapy with ABLC was added to itra-
conazole, the response rate was low (27%), indicating the 
possibility of maximizing therapy in desperately ill patients. 
A 37% response rate was seen in 19 patients infected with 
Aspergillus terreus, an innately polyene-resistant species. 
As expected, response rate (cured + improved) with ABLC 
in those intolerant of AmB (54%) was better compared with 
those receiving ABLC after failure of prior therapy (39%). 
Similar response rates were seen in patients receiving ABLC 
as ﬁ  rst-line or second-line treatment (intolerant of or refrac-
tory to prior therapy). Recognizing the fact that the CLEAR 
database and the study comparing voriconazole to AmB 
deoxycholate have large differences, the response rates for 
ABLC and voriconazole were similar.
The response rate with ABLC therapy in hematopoietic 
stem cell recipients (n = 85) with ABLC was the lowest 
(7%–40%) in single-site and multiple-site infections among 
different groups (Ito et al 2005). Response rate was 31% 
(26 of 85 patients) overall, and 21% (5 of 24) in those with 
graft versus host disease. When ABLC was administered as 
ﬁ  rst-line therapy, the response rate was slightly improved 
(41%), perhaps implying earlier therapy may have a better 
outcome. This compares favorably to the 31% response rate 
of voriconazole among allogeneic stem cell recipients in the 
Herbrecht study. Serum creatinine doubled in 12% patients 
(10 of 85) and 2% required dialysis.
In the emergency-use study, 42% had complete or partial 
response with ABLC for invasive aspergillosis (n = 130) 
(Walsh et al 1998). Response in single organ extrapulmonary 
aspergillosis was better than that with cases of disseminated 
aspergillosis.
Voriconazole is useful as primary therapy for invasive 
aspergillosis while posaconazole may be considered for sal-
vage therapy (approved in Europe). Itraconazole, given its 
drug interaction proﬁ  le and suboptimal bioavailability, is no 
longer an attractive agent. Among echinocandins, caspofungin 
is approved for use in salvage therapy; data on primary therapy 
are not available. Thus, the role of polyene therapy in IA, as in 
candidiasis, has diminished. Among combination drug therapy 
strategies, a newer azole (eg, voriconazole) plus an echinocan-
din, based on in vitro and animal data, is currently favored.
Zygomycosis
Zygomycosis is a serious infection of increasing frequency, 
particularly in compromised hosts (Kontoyiannis et al 2005; 
Roden et al 2005). Among the newer azoles, voriconazole 
has no activity against zygomycetes, while oral posacon-
azole has been studied in the salvage setting in a limited 
number of patients (n = 91) with a favorable outcome (60% 
complete or partial response at 12 weeks, with 21% stable 
response), particularly in the setting of surgical debridement 
Table 3 Clinical response to treatment with ABLC in patients with proven invasive aspergillosis by prior treatment status
Second-line therapy with ABLC First-line therapy with ABLC
Clinical 
response
Unknown
(n = 11)
Refractory
to prior
antifungal 
therapy
(n = 157)
Underlying
renal disease/
prior antifungal 
therapy (n = 9)
Intolerant
of prior
antifungal
therapy
(n = 50)
Underlying
renal disease
no prior
antifungal
therapy
(n = 88)
No prior 
antifungal 
therapy/
no renal
disease
(n = 51)
Other
(n = 2)
Total
(n = 368)
Cured – 15 (10) – 4 (8) 16 (18) 6 (12) 1 (50) 42 (11)
Improved 2 (18) 45 (29) 7 (78) 23 (46) 30 (34) 13 (26) – 120 (33)
Stable 2 (18) 33 (21) 1 (11) 12 (24) 20 (23) 10 (20) – 78 (21)
Deteriorated 7 (64) 64 (41) 1 (11) 11 (22) 22 (25) 22 (43) 1 (50) 128 (35)
Note: Data are no. (%) of patients.
From Chandrasekar and Ito (2005).
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and improvement of underlying immune deﬁ  cit (van Burik 
et al 2006).
In the CLEAR database (n = 64), a median daily dose of 
4.8 mg/kg ABLC resulted in cure or improvement in 52% 
and in stable disease in 20% of patients (Larkin and Montero 
2003). With ABLC as second-line therapy (n = 35), response 
rates in those refractory to prior therapy and those intolerant 
of prior therapy were 48% (11 of 23 patients) and 58% (7 of 
12 patients) respectively. As expected, surgical debridement 
was performed in most patients.
Therapy with a lipid form of AmB (at 5–10 mg/kg/d) 
is the currently accepted approach for zygomycosis until 
more data with posaconazole become available. In current 
practice, after stabilization is achieved with polyene therapy, 
switching over to oral posaconazole (400 mg twice daily) 
is becoming common. Duration of therapy remains unclear, 
and is usually based on control of infection and correction 
of underlying immune deﬁ  cit. Given the high frequency of 
nephrotoxicity with AmB deoxycholate, this formulation is 
no longer appropriate for zygomycosis.
Cryptococcosis
With the availability of antiretroviral therapy for the 
management of AIDS, the incidence of cryptococcosis has 
markedly declined. Cryptococcosis is one of the few fungal 
infections for which a polyene is still advocated as primary 
therapy. AmB deoxycholate (0.7 mg/kg/d) plus ﬂ  ucytosine 
(100 mg/kg/d) for an initial 2 weeks followed by ﬂ  uconazole 
(400 mg/d) for an additional 8 weeks is widely accepted as 
the standard treatment (Saag et al 2000).
In the CLEAR database, 101 patients with cryptococcoccal 
infection were evaluable (Baddour et al 2005). Response rates 
(cured or improved) with ABLC were 65% (51 of  78 patients) 
for patients with central nervous system (CNS) involvement 
and 70% (16 of 23) for those without CNS involvement. 
Response rates were 56% (19 of 34 patients) for patients who 
were refractory to prior antifungal therapy, and 65% (11 of 
17) for patients who were intolerant of prior fungal therapy. 
First-line therapy (n = 44) achieved a 75% response rate 
while second-line therapy (n = 56) had a 59% response rate. 
In the compassionate-use protocol, 11 patients were given 
ABLC (median dose 4.9 mg/kg/d) for cryptococcosis; these 
patients were refractory to or intolerant of AmB or had pre-
existing renal impairment (Walsh et al 1998). Seven of 11 
had complete or partial response. In a study comparing ABLC 
(5 mg/kg/d) and AmB deoxycholate (0.7–1.2 mg/kg/d) for 
the treatment of patients with AIDS-associated cryptococcal 
meningitis, clinical response of 86% (18 of 21 patients) was 
observed with the former and 65% (11 of 17 patients) with 
the latter (Sharkey et al 1996).
From the above body of data, it may be concluded that 
ABLC is an effective drug for the treatment of cryptococcal 
infection in patients with refractory to or intolerant of prior 
therapy with AmB deoxycholate. Also, ABLC appears at 
least as effective as AmB deoxycholate as initial therapy. 
Currently, azoles (including voriconazole and posaconazole) 
or echinocandins are not considered the drugs of choice for 
initial therapy of cryptococcosis.
Fusariosis
Fusariosis is an uncommon fungal infection. Usually it is seen 
in compromised patients with prolonged neutropenia or after 
cortiosteroid use for graft-versus host disease in allogeneic 
stem cell transplant patients. Often the infection presents with 
cutaneous lesions and positive blood cultures. The organism, 
in clinical laboratories, is not identiﬁ  ed to the species level; 
some species are susceptible to AmB (not to voriconazole), 
while others may be susceptible only to voriconazole.
Salvage therapy with voriconazole yielded an overall 
response rate of 46% in patients with invasive fusa-
riosis (Perfect et al 2003). In the CLEAR database, ABLC 
was administered as ﬁ  rst-line therapy to 8 of 28 (29%) 
patients and as second-line treatment to 20 of 28 (71%) 
patients; most had infection refractory to prior antifungals 
(43%) or demonstrated intolerance of prior antifungals (29%) 
(Perfect 2005). ABLC was administered at a median dose of 
4.5 mg/kg/d for a median duration of 20.5 days. Of the 26 
evaluable patients, 12 (46%) were cured or improved, and 
3 (12%) were stabilized after ABLC therapy. Patients with 
normal absolute neutrophil counts (ANC  500 cells/mm3) 
at the end of therapy had better outcomes than those who did 
not, regardless of neutrophil count at baseline. Median serum 
creatinine levels were 1.15 mg/dL and 1.40 mg/dL at the start 
and end of therapy, respectively. In the compassionate-use 
protocol, 9 of 11 of patients with fusariosis had a complete 
or partial response with ABLC (Walsh et al 1998).
Histoplasmosis
Polyenes and itraconazole are the drugs of choice for the 
treatment of histoplasmosis. Clinical response rate with 
itraconazole or liposomal AmB is excellent (85%); however, 
for patients with positive blood culture, more rapid clearance 
was achieved with liposomal amphotercin B (Wheat et al 
2001). When liposomal AmB at 3 mg/kg/d was compared 
with AmB deoxycholate at 0.7 mg/kg/d for therapy of 
disseminated histoplasmosis in AIDS patients (n = 81), Therapeutics and Clinical Risk Management 2008:4(6) 1290
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the former had improved success and higher survival rate 
(Johnson et al 2002).
In the CLEAR database, 21 of 25 patients (84%) with 
histoplasmosis had complete or partial response with ABLC 
therapy (Perfect 2005). In patients with severe or life-
threatening histoplasmosis, therapy with a polyene drug is 
preferred to an azole.
Other molds
In the CLEAR database, patients with 59 other mold infections 
were assessed (Perfect 2005). Pathogenic fungi were Blasto-
myces sp (n = 17), Coccidioides sp (n = 8) and Scedosporium 
(n = 11). Median daily dose of ABLC was 4 mg/kg/d and the 
median duration of therapy was 14 days. Cured or improved 
responses were seen in: blastomycosis – 9 of 14 patients; 
coccidioidomycosis – 5 of 8 patients and scedosporiosis – 1 of 8 
patients. Responses in other infections were: Acremoniun (2 of 
4 patients), Curvularia (3 of 4 patients), Alternaria (3 of 3 
patients), Scopulariopsis (0 of 3 patients), Trichoderma 
(2 of 2 patients), Dactylaria (1 of 2 patients), Exophiala 
(1 of 2 patients), Bipolaris (1 of 1 patient), Phoma and 
Paecilomyces (0 of 2 patients).
Special populations
Children
Limited data are available for antifungal therapy in pediatric 
patients (Herbrecht et al 2001). In the CLEAR registry, 548 
children and adolescents were enrolled to receive ABLC 
therapy (Wiley et al 205). Most were either intolerant of 
or refractory to conventional antifungal therapy. All had 
cancer, or had received a bone marrow, cord blood, or solid 
organ transplant and then received ABLC for documented 
or suspected invasive fungal infection. A complete or partial 
response was seen in 55% patients with an additional 17% 
with a stable outcome (Table 4). The drug was well tolerated 
with modest renal impairment; it is noteworthy that 72% study 
patients had received 1 or more concomitant nephrotoxins.
A subset analysis of the compassionate-use study 
demonstrated the efﬁ  cacy and safety of ABLC in 111 pediatric 
patients aged 21 days to 16 years (Walsh et al 1998). Seventy 
(38 of 54 patients) had complete or partial response, and no 
signiﬁ  cant changes in serum creatinine levels occurred from 
baseline to end of therapy. In a limited retrospective study 
of 46 pediatric patients (mean age 10 ± 5 years) with inva-
sive fungal infection and refractory to or intolerant of prior 
antifungal therapy, therapy with ABLC had response rates 
of 89% for systemic candidiasis (17 of 19 patients) and 78% 
for invasive aspergillosis (18 of 23 patients) (Herbrecht et al 
2001). The drug, given at a mean daily dose of 4.1 mg/kg/d 
for a mean duration of 39 days, was well tolerated.
In neonates with invasive canididiasis, ABLC was well 
tolerated and effective both as ﬁ  rst-line therapy and in those 
who failed to respond to prior systemic antifungal treatment 
or had drug-associated nephrotoxicity and/or underlying 
renal disease (Adler-Shohet et al 2001).
Elderly
From the CLEAR database, Hooshmand-Rad et al (2005) 
published their analysis of 572 elderly patients who received 
ABLC for proven or suspected invasive fungal infection. 
Clinical response was 56% in those 65 years of age 
(n = 572) and 51% in those 65 years of age (n = 2930) 
(p = 0.049). Despite higher pretreatment serum creatinine 
values in the elderly (1.7 mg/dL vs 1.4 mg/dL), both groups 
showed only a 0.1 mg/ dL rise in median serum creatinine 
level from baseline to end of therapy (p = 0.54).
Solid organ transplant recipients
Linden et al (2000) reviewed open-label, second-line treatment 
studies of ABLC for severe life-threatening invasive fungal 
Table 4 Clinical response to treatment with ABLC, according to age, in evaluable patients with documented fungal infection (N = 255)
Clinical response All (n = 255) 0–3 mo (n = 32) 4 mo–1 yr (n = 19) 2–11 yr (n = 87) 12–20 yr (n = 117)
Cured 74 (29.0)* 19 (59.4) 6 (31.6) 23 (26.4) 26 (22.2)
Improved 65 (25.5) 4 (12.5) 6 (31.6) 24 (27.6) 31 (26.5)
Stable 43 (16.9) 3 (9.4) 5 (26.3) 19 (21.8) 16 (13.7)
Deteriorated 73 (28.6) 6 (18.8) 2 (10.5) 21 (24.1) 44 (37.6)
Cured + improved 139 (54.5) 23 (71.9) 12 (63.2) 47 (54.0) 57 (48.7)
Cured + improved + 
stable
182 (71.4) 26 (81.3) 17 (89.5) 66 (75.9) 73 (62.4)
* (%)
Reproduced with permission from Wiley JM, Seibel NL, Walsh TJ. 2005. Efﬁ  cacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal 
infections. Pediatr Infect Dis J, 24:167–174. © Lippincott Williams & Wilkins.
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infections in solid organ recipients who were refractory 
to or intolerant of prior antifungal therapy (mostly AmB 
deoxycholate) or had pre-existing renal disease. There were 
79 solid organ transplant recipients (heart–25; liver–20; 
kidney–17; lung–11; pancreas–1; multiple–5) who received 
ABLC (median dose 4 .6 mg/kg/d) for a median duriation of 
28 days for the following infections: aspergillosis (n = 39), 
candidiasis (n = 20); zygomycosis (n = 8); cryptococcosis and 
histoplasmosis (n = 3 each); and blastomycosis, cladosporio-
sis, fusariosis, and infection due to Bipolaris hawaiiensis, 
Dactylaria gallopova, and an unspeciﬁ  ed fungus (n = 1 each). 
In the 67 evaluable patients, response rate was 58%. Response 
rates for candidiasis and aspergillosis were 47% and 71%, 
respectively. Mean baseline serum creatinine was 3.2 mg/dL; 
64 patients (81%) had stable (n = 37) or improved (n = 27) 
serum creatinine at the end of therapy.
Stem cell recipients
Both emergency-use study (59 patients) and the CLEAR 
database (800 patients) included stem cell recipients with 
invasive fungal infection. Among the 59 patients, 31 (53%) 
responded to ABLC treatment. Improvement in serum cre-
atinine was noted at weeks 1 to 3 and 6 (Wingard 1997). In 
the CLEAR registry, response rates with ABLC among stem 
cell recipients were 40% for invasive candidiasis, 40% for 
invasive aspergillosis (single site infection), and 13% (1 of 
8 patients) for invasive fusariosis.
Safety
Lipid-based formulations of AmB cause less nephrotoxicity and 
hypokalemia than AmB deoxycholate (Barrett et al 2003).
Walsh et al (1998) reported that ABLC therapy was 
associated with a signiﬁ  cant improvement in renal function, 
particularly among those with pre-existing renal insufﬁ  ciency 
or nephrotoxicity caused by AmB deoxycholate. Serum 
creatinine levels decreased from baseline during the course 
of ABLC therapy (p  0.02), and renal function improved 
from week 1 to week 6 (p  0.0003) in 162 patients with 
serum creatinine values 2.5 mg/dL on baseline. Table 5 
shows the CLEAR data for change in renal function in 3514 
ABLC-treated patients (Alexander and Wingard 2005). 
Serum creatinine values doubled in 13% of patients, and new 
dialysis was needed in 3% of patients. Risk factors identiﬁ  ed 
for nephrotoxicity were concomitant treatment with poten-
tially nephrotoxic agents and a baseline serum creatinine 
value of 2 mg/dL. In allogeneic stem cell recipients, 17% 
demonstrated end-of-therapy doubling of serum creatinine 
levels. In the pediatric population, there were few clinically 
signiﬁ  cant deleterious effects on renal function (Wiley et al 
2005). There was no signiﬁ  cant difference between the rate 
of new hemodialysis versus baseline hemodialysis. Whether 
rates of nephrotoxicity vary between ABLC and liposomal 
AmB remains controversial. While several studies have sug-
gested that the rates of nephrotoxicity are similar, Wingard 
et al reported that the baseline creatinine values doubled after 
2 weeks in 14.8% (12 of 81 patients) of patients receiving 
liposomal AmB, and in 42.3% (33 of 78 patients) receiving 
ABLC (Cannon et al 2001; Fleming et al 2001; Wingard et al 
2000). Preliminary data of a recent meta-analysis suggested 
that the rates are similar (Safdar et al 2007).
Transient infusion-related events include fever, chills, 
nausea, and vomiting; most abate within a few days of 
initiation of ABLC, and often are managed with premedi-
cation. Such infusion-related effects appear to be less with 
liposomal AmB. Other adverse events with ABLC include 
hepatotoxicity, hyperkalemia, hypertension, and pulmonary 
reactions.
Are AmB and lipid forms of AmB 
obsolete?
Despite serious nephrotoxic potential, AmB deoxycholate and 
lipid forms of AmB have long enjoyed clinical use, primarily 
because other systemic antifungal drugs have been lacking. 
Arrival of newer triazoles and echinocandins in the past few 
years has changed the situation; because of their safety and 
efﬁ  cacy proﬁ  les, these drugs are steadily edging out polyenes 
from clinical practice. Nevertheless, AmB has a long track 
record, possesses a broad spectrum of antifungal activity, 
and remains useful particularly in the setting of critically 
ill patients with invasive fungal disease where the etiologic 
pathogen is not identiﬁ  ed. Moreover, resistance to AmB has 
remained rare despite decades of its use, while in contrast, 
several reports of resistance to azoles and/or echinocandins 
among yeasts and molds have already emerged.
Table 6 lists the potential clinical situations where AmB 
deoxycholate or the lipid forms of AmB continue to serve 
as useful drugs in clinical practice. With zygomycosis, until 
more data become available with posaconazole, the polyenes 
remain the primary drugs for initial therapy. As higher doses 
are generally favored, lipid forms of AmB are preferred to 
AmB deoxycholate to minimize nephrotoxicity. Likewise, in 
the management of serious cryptococcosis (eg, cryptococcal 
meningitis, disseminated cryptococosis), a polyene drug 
in combination with ﬂ  ucytosine is recommended; azoles 
(ie, ﬂ  uconazole) may be useful in maintenance therapy while 
echinocandins have no reliable activity against cryptococcus. Therapeutics and Clinical Risk Management 2008:4(6) 1292
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Table 5 Renal function in ABLC-treated patients with fungal infections
End-of-therapy renal function parameter
Patient group Baseline S-Cr 
level, median 
(range), Mg/dL
Change in CCr 
median (range), 
mL/min
p Doubling of 
baseline S-Cr 
level No. (%)
of patients
p Increase in 
S-Cr level To 
 2.5 mg/dL 
No. (%) of 
patients
pN e w  
dialysis 
No. (%) of 
patients
p
All patients (N = 3514) 1.4 (0.08–6) –3 (–119 to 118) – 468 (13) – 412 (12) – 92 (3) –
Age group
  18 years
 (n−454)
0.7 (0.1–6) 0 (–105 to 108) – 71 (16) – 27 (6) – 12 (3) –
  18 years (n = 3048) 1.6 (0.08–6) –3 (–119 to 118) 0.008 396 (13) 0.110 385 (13) 0.001 80 (3) 0.975
Status prior to start of 
ABLC therapya
   Refractoryb 
(n = 1411)
1.2 (0.08–6) –5 (–111 to 99) 0.033 220 (16) 0.282 157 (11) 0.397 25 (2) 0.209
   Underlying renal 
disease, prior antifungal 
therapy (n = 84)
2 (0.3–6) 0.5 (–107 to 52) 0.001 11 (13) 0.307 14 (17) 0.056 4 (5) 0.027
   Underlying renal 
disease, no prior 
antifungal therapy
(n = 945)
2 (0.15–6) 0 (–99 to 118) 0.001 83 (9) 0.0091 133 (14) 0.025 44 (5) 0.001
 Intolerancec (n = 573) 1.4 (0.2–6) 0 (–108 to 101) 0.001 60 (11) 0.001 54 (9) 0.855 14 (2) 0.072
   No prior antifungal 
therapy/no renal 
disease (n = 431)
1 (0.1–6) –10 (–117 to 101) – 77 (18) – 42 (10) – 4 (1) –
 Prior  treatment
   No prior Amb
(n = 2056)
1.3 (0.08–6) –5 (–119 to 118) 0.001 311 (15) 0.001 230 (11) 0.290 50 (2) 0.408
Prior AmB (n = 1398) 1.6 (0.19–6) 0 (–117 to 101) – 146 (10) – 173 (12) – 40 (3) …
Note: Statistical analysis was performed by using the median scores test for continuous variables and χ2 or Fisher’s exact test, as appropriate, for categorical variables.
Abbreviations: AmB, amphotericin B deoxycholate; CCr, predicted creatinine clearance; S-Cr, serum creatinine.
aP values in this subsection compare each category with patients in the “no prior antifungal medication/no underlying renal disease” category.
b22% of these patients also had underlying renal disease.
cIntolerance included infusion-related toxicity, increasing S-Cr level, or hepatotoxicity.
Reproduced from Alexander BD, Wingard JR. 2005. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis, 40(Suppl 6):S414–S21. Copyright © 2005. 
University of Chicago Press. All rights reserved.
Serious endemic mycoses warrant initial therapy with a 
polyene drug. For therapy of fusariosis, a polyene drug 
and/or voriconazole is recommended for initial therapy, 
since the different species have variable susceptibility, and 
most hospital laboratories do not identify this organism 
to the species level nor perform susceptibility studies. 
Although voriconazole has become the drug of choice 
for invasive aspergillosis, refractoriness or intolerance 
to the drug may be encountered; in such cases, a lipid 
form of AmB serves as an effective alternative. Finally, 
given its broad spectrum of activity, AmB remains useful 
as empiric therapy when an invasive mold infection par-
ticularly zygomycosis, is strongly suspected. In general, 
lipid forms of AmB are preferred to AmB deoxycholate 
in the aforementioned situations in view of the reduced 
Table 6 Amphotericin B – clinical indications
  Invasive  aspergillosis
  • Voriconazole  intolerance/failure
  •  ? in combination therapy with an echinocandin
  Cryptococcosis 
  •   Meningitis/Diffuse Pneumonia
        In combination with ﬂ  ucytosine (many centers may use 
amphotericin B deoxycholate)
   Histoplasmosis, blastomycosis, coccidioidomycosis 
  • Severe  infection
  Zygomycosis 
  •  Higher than usual dose (5 mg/kg/d)
  Fusariosis* 
  •  ? in combination with voriconazole
  Empiric therapy 
  •  Suspected invasive mold disease
*Different species of fusarium vary in their susceptibility to amphotericin B and 
voriconazole, and most laboratories do not identify the pathogen to the species level.Therapeutics and Clinical Risk Management 2008:4(6) 1293
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nephrotoxic potential of the former. It is worth emphasizing 
that superiority in efﬁ  cacy of the lipid forms of AmB over the 
deoxycholate formulation has not been established.
In children and neonates, AmB is remarkably well tol-
erated without signiﬁ  cant nephrotoxicity, hence use of the 
polyene may continue in this population. Finally, in resource-
poor countries, since AmB deoxycholate is likely to be much 
less expensive than the newer drugs including the lipid forms 
of AmB, the polyene may remain an important drug in their 
antifungal drug armamentarium.
Conclusion
AmB lipid complex (ABLC) is an effective and safe drug 
in the treatment of invasive fungal infections caused by 
yeasts and molds in many diverse compromised patient 
populations. ABLC causes nephrotoxicity particularly when 
used along with other nephrotoxic drugs, but it is much less 
toxic than AmB deoxycholate formulation. Its efﬁ  cacy is 
well established in patients with infection refractory to AmB 
deoxycholate or in patients who are intolerant of the same 
formulation. The drug has not been rigorously evaluated for 
use as primary therapy. Its role in current clinical practice 
is markedly curtailed, largely due to the recent availability 
of effective and better tolerated newer triazoles and echino-
candins. However, concerns with the newer agents such as 
limited spectrum of activity, emergence of drug-resistant 
fungi and signiﬁ  cant drug-drug interactions assure the con-
tinued clinical use of the polyene class of drugs.
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